Table 2. Administration status of antihypertensive agentsa.
| At the start of olmesartan therapy (baseline) (n=21 341) | 16 weeks (n=21 341) | |
|---|---|---|
| Dose of olmesartan, mean±s.d. (mg per day) | 18.2±7.0 | 18.8±8.3 |
| 0 (discontinuation) | 0 (0.0) | 512 (2.4) |
| 0<−5 (mainly 5) | 502 (2.4) | 489 (2.3) |
| 5<−10 (mainly 10) | 5450 (25.5) | 4455 (20.9) |
| 10<−20 (mainly 20) | 14 193 (66.5) | 13 982 (65.5) |
| 20<−40 (mainly 40) | 1196 (5.6) | 1903 (8.9) |
| Receiving concomitant antihypertensive agents | 8280 (38.8) | 9588 (44.9) |
| Calcium channel blocker | 7245 (33.9) | 8389 (39.3) |
| β-Blocker | 1276 (6.0) | 1386 (6.5) |
| Diuretic | 961 (4.5) | 1403 (6.6) |
| α-Blocker | 436 (2.0) | 509 (2.4) |
| Angiotensin-converting enzyme inhibitor | 309 (1.4) | 309 (1.4) |
| Angiotensin II receptor blocker | 160 (0.7) | 161 (0.8) |
| Other | 74 (0.3) | 112 (0.5) |
| No. of antihypertensive drugs (including olmesartan) | 1.5±0.7 | 1.6±0.8 |
a
Values are n (%) unless otherwise specified.